The Swiss voice in the world since 1935

Swiss giant Roche given green light for lung cancer drug in Canada

Roche: Canadian green light for Alecensaro drug
Roche: Canadian green light for Alecensaro drug Keystone-SDA

Roche has been granted marketing authorisation for its drug Alecensaro by Health Canada. Alecensaro is an adjunct therapy for patients with early-stage ALK-positive lung cancer.

Want to read our weekly top stories? Subscribe here.

Health Canada, the Canadian regulatory authority for therapeutic products, issued the authorisation on June 27 citing an “urgent unmet need”, as stated in a press release published on Tuesday.

More

Data from the phase III Alina study shows that Alecensaro (alectinib) reduced the risk of recurrence or death by 76% compared to chemotherapy alone in patients with early-stage ALK-positive lung cancer who had undergone tumour removal. Normally, approximately half of early-stage patients experience disease relapse following tumour surgery.

Lung cancer is one of the most common causes of cancer-related death worldwide. Approximately one in 15 women and one in 14 men in Canada will develop this type of cancer in their lifetime, Roche pointed out.

Translated from French by DeepL/sp

This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.

If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.

External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Daily news

Get the most important news from Switzerland in your inbox.

Daily

The SBC Privacy Policy provides additional information on how your data is processed.

Popular Stories

Most Discussed

News

F/A-18 take-offs and landings at Bern-Belp Airport

More

F/A-18s take off and land at Bern Airport

This content was published on The Swiss Armed Forces are training their fighter jets in Bern to fly from a civilian base. The exercise at Bern Airport will last until Wednesday.

Read more: F/A-18s take off and land at Bern Airport
cern

More

Plans materialise for new particle accelerator in Geneva

This content was published on Preparations for a huge new particle accelerator in Geneva have reached a milestone. After several years of work, a feasibility study for the project has now been finalised.

Read more: Plans materialise for new particle accelerator in Geneva
More Russian assets frozen in Switzerland

More

More Russian assets frozen in Switzerland

This content was published on The value of frozen Russian assets in Switzerland currently stands at CHF7.4 billion ($8.4 billion), the Swiss government announced on Tuesday.

Read more: More Russian assets frozen in Switzerland
Increase in business start-ups in the 1st quarter

More

Increase in Swiss business start-ups in Q1

This content was published on The number of business start-ups in Switzerland accelerated in the first three months of the year, with entrepreneurs being particularly dynamic in Central Switzerland, Basel and Geneva.

Read more: Increase in Swiss business start-ups in Q1

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR